OSAS-COPD重叠综合征患者新型炎症生物标志物研究进展

Research Progress of New Inflammation Biomarkers in Patients with OSAS-COPD Overlap Syndrome

阻塞性睡眠呼吸暂停(OSAS)与慢性阻塞性肺疾病(COPD)是临床上极为常见的呼吸系统疾病,OSAS和COPD两者并存时时称为呼吸重叠综合征(OS)。尽管重叠综合征的机制暂不明确,但睡眠呼吸功能紊乱和间歇性缺氧所致的全身及局部气道炎症反应、氧化应激在疾病发生、发展及相互作用之间起着至关重要的作用,这使得OS的病理生理改变更复杂,预后更差,死亡率更高。因此通过简单且易获得的炎症指标对OS患者进行危险分层,早期干预并改善预后尤为重要。近年来,与OS相关的新型炎症生物标志物,引起了国内外研究人员的关注,本研究旨在探讨OSAS和COPD重叠综合征患者新型炎症生物标志物的作用及机制。为临床上的早期诊断和治疗提供新的思路和方法,从而改善患者的预后和生活质量。

Obstructive sleep apnea (OSAS) and chronic obstructive pulmonary disease (COPD) are commonly encountered respiratory diseases in clinical practice. Their coexistence, known as the overlap syn-drome (OS), significantly complicates patient management. The pathogenesis of OS, although not fully understood, is believed to be influenced by systemic and localized airway inflammation as well as oxidative stress, which are consequences of sleep-disordered breathing and intermittent hypox-ia. These factors contribute to the complexity of pathophysiological changes in OS, invariably lead-ing to poor prognosis and increased mortality. Given this, the stratification of patient risk using simple and accessible inflammatory markers for early intervention becomes vitally important, po-tentially improving prognosis. In recent years, emergent inflammatory biomarkers linked to OS have garnered the attention of researchers globally. Our study delves into the role and mechanism of these novel inflammatory biomarkers in patients with OSA and COPD. By doing so, we seek to pi-oneer new approaches for the early clinical diagnosis and treatment to enhance patient prognosis and life quality.